FDA Approves the New Insomnia Drug Belsomra

The U.S. Food and Drug Administration (FDA) has recently approved a new drug to treat insomnia called Belsomra by Merck & Co.

The new drug works by adjusting Orexin, a neurotransmitter than makes us feel energized or awake. As many dealing with insomnia or anxiety simply just can't sleep, despite exhaustion, Belsomra works by signaling this neurotransmitter to allow users to get the rest they need.

"Today's approval of BELSOMRA allows for the introduction of a new treatment option for patients suffering from insomnia," said Dr. David Michelson, vice president, Neurosciences, Merck Research Laboratories, in a statement. "BELSOMRA is the result of more than a decade of Merck research in neuroscience and provides tangible evidence of our long-standing commitment to innovation."

Not only is sleep essential for health and overall well-being, but it's connected to a range of other health issues. Too little sleep can exacerbate pre-existing conditions and it can lead to an increased risk of certain diseases, such as hypertension, obesity, diabetes, depression and even certain types of cancer. Studies have also shown that insufficient rest can increase the risk of industrial errors as well as motor vehicle accidents if the driver falls asleep unintentionally.

The FDA recommends that new users start out taking the lowest strength of Belsomra. Health officials also advise that it is taken when a person has at least seven hours to sleep. Maximum dosage should not exceed 20 milligrams per day.

Merck & Co. suggest that the latest Belsomra has lesser side effects than current sleeping pills and will be available in four different strengths at 5, 10, 15 and 20 milligram doses.